Adverse events ‐ weight loss · adults with Parkinson's disease
GLP‐1 receptor agonists showed no clear difference in adverse events ‐ weight loss compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ weight loss · adults with Parkinson's disease
1 finding from 1 review
Adverse events (12 (12, 26)) · people with congenital heart disease.
1 finding from 1 review
Adverse events Self‐reported · patients with non‐specific chronic low back pain
Acupuncture showed no clear difference in adverse events Self‐reported compared with usual care (low certainty).
1 finding from 1 review
Adverse events Self‐reported · patients with non‐specific chronic low back pain
Acupuncture showed no clear difference in adverse events Self‐reported compared with sham intervention (low certainty).
1 finding from 1 review
Adverse events Self‐reported · patients with non‐specific chronic low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (split-mouth) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide led to lower adverse events (split-mouth) compared with cryotherapy; GRADE not reported.
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ at one year · children with familial hypercholesterolemia
The intervention showed no clear difference in adverse events ‐ at one year (moderate certainty).
1 finding from 1 review
Adverse events Men and women · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection, diagnosed by cell…
Azithromycin probably leads to lower adverse events Men and women compared with doxycycline (moderate certainty).
1 finding from 1 review
SAEs · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with irritable bowel syndrome
1 finding from 1 review
SAEs · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with irritable bowel syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events up to week 12 · Patients with active Crohn's disease
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events up to week 12 · Patients with active Crohn's disease
Two infusions of natalizumab (6 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events up to week 12 · Patients with active Crohn's disease
Three infusions of natalizumab (300 mg) showed no clear difference in adverse events up to week 12 compared with placebo (high certainty).
1 finding from 1 review